Your browser doesn't support javascript.
loading
Treatment of cutaneous and/or soft tissue manifestations of corticosteroids refractory chronic graft versus host disease (cGVHD) by a total nodal irradiation (TNI).
Peyraga, Guillaume; Lizee, Thibaut; Gustin, Pierre; Clement-Colmou, Karen; Di Bartolo, Christelle; Supiot, Stephane; Mahe, Marc-Andre; François, Sylvie; Mege, Martine.
Afiliação
  • Peyraga G; Department of Radiotherapy, Integrated Center of Oncology, ICO Paul Papin, Angers, France.
  • Lizee T; Department of Radiotherapy, Integrated Center of Oncology, ICO Paul Papin, Angers, France.
  • Gustin P; Department of Radiotherapy, Integrated Center of Oncology, ICO Paul Papin, Angers, France.
  • Clement-Colmou K; Department of Radiotherapy, Integrated Center of Oncology, ICO René Gauducheau, Saint-Herblain, France.
  • Di Bartolo C; Department of Medical Physics, Integrated Center of Oncology, ICO Paul Papin, Angers, France.
  • Supiot S; Department of Radiotherapy, Integrated Center of Oncology, ICO René Gauducheau, Saint-Herblain, France.
  • Mahe MA; Department of Radiotherapy, Integrated Center of Oncology, ICO René Gauducheau, Saint-Herblain, France.
  • François S; Department of Blood Diseases, University Hospital of Angers, Angers, France.
  • Mege M; Department of Radiotherapy, Integrated Center of Oncology, ICO Paul Papin, Angers, France.
Clin Transplant ; 31(4)2017 04.
Article em En | MEDLINE | ID: mdl-28181304
ABSTRACT
The management of corticosteroids refractory chronic graft versus host disease (cGVHD) remains controversial. Retrospective analysis of patients treated at the Integrated Center of Oncology by total nodal irradiation (TNI) was performed to evaluate its therapy potency. TNI delivers a dose of 1 Gy in a single session. The delimitation of the fields is clinical (upper limit external auditory meatus; lower limit mid-femur). No pre-therapeutic dosimetry scanner was necessary. Evaluation of the efficacy was by clinical measures at 6 months after the treatment. Twelve patients were treated by TNI between January 2010 and December 2013. TNI was used in second-line treatment or beyond. The median time between allograft and TNI was 31.2 months, and the median time between the first manifestations of cGVHD and TNI was about 24.2 months. Of the 12 patients, nine had a clinical response at 6 months (75%), including five complete clinical responses (41.6%). Five patients could benefit from a reduction of corticosteroid doses. Three patients had hematologic toxicity. TNI could be considered as an option for the treatment of a cutaneous and/or soft tissues corticosteroids refractory cGVHD. However, prospective randomized and double-blind trials remain essential to answer the questions about TNI safety and effectiveness.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dermatopatias / Neoplasias de Tecidos Moles / Corticosteroides / Transplante de Células-Tronco Hematopoéticas / Resistencia a Medicamentos Antineoplásicos / Doença Enxerto-Hospedeiro / Linfonodos Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dermatopatias / Neoplasias de Tecidos Moles / Corticosteroides / Transplante de Células-Tronco Hematopoéticas / Resistencia a Medicamentos Antineoplásicos / Doença Enxerto-Hospedeiro / Linfonodos Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article